Abstract:Background/Aims: Histone deacetylases (HDACs) play a critical role in the regulation of gene transcription, cardiac development, and diseases. The aim of this study was to investigate whether the inhibition of HDACs improves cardiac remodeling and its underlying mechanisms in a mouse myocardial infarction (MI) model. Methods: The HDAC inhibitor trichostatin A (TSA, 0.1 mg/kg/day) was administered via daily intraperitoneal injections for 8 consecutive weeks after MI in C57/BL mice. Echocardiography and tissue histopathology were used to assess cardiac function. Cultured neonatal rat cardiac fibroblasts (NRCFs) were subjected to simulated hypoxia in vitro. Autophagic flux was measured using the tandem fluorescent mCherry-GFP-LC3 assay. Western blot was used to detect autophagic biomarkers. Results: After 8 weeks, the inhibition of HDACs in vivo resulted in improved cardiac remodeling and hence better ventricular function. MI was associated with increased LC3-II expression and the accumulation of autophagy adaptor protein p62, indicating impaired autophagic flux, which was reversed by TSA treatment. Cultured NRCFs exhibited increased cell death after simulated hypoxia in vitro. Increased cell death was associated with markedly increased numbers of autophagosomes but not autolysosomes, as assessed by punctate dual fluorescent mCherry-green fluorescent protein tandem-tagged light chain-3 expression, indicating that hypoxia resulted in impaired autophagic flux. Importantly, TSA treatment reversed hypoxia-induced impaired autophagic flux and led to a 40% decrease in cell death. This was accompanied by improved mitochondrial membrane potential. The beneficial effects of TSA therapy were abolished by RNAi intervention targeting LAMP2; likewise, in vivo delivery of chloroquine abolished the TSA-mediated cardioprotective effects. Conclusion: Our results provide evidence that the HDAC inhibitor TSA prevents cardiac remodeling after MI and is dependent on restoring autophagosome processing of cardiac fibroblasts. (C) 2018 The Author(s) Published by S. Karger AG, Basel

HDAC Inhibition: A Novel Therapeutic Approach for Attenuating Heart Failure by Suppressing Cardiac Remodeling.

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Cardiac Remodeling: Novel Pathophysiological Mechanisms and Therapeutic Strategies

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Gene expression profiles, potential targets and treatments of cardiac remodeling

The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure

Targeting transcription in heart failure via CDK7/12/13 inhibition

Targeting histone deacetylase in cardiac diseases

Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets

The role of Nrf2-mediated pathway in cardiac remodeling and heart failure.

Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis

Cardiac structural remodeling in hypertensive cardiomyopathy

Abstract 13767: Cardiac Reprogramming Reduces Fibrosis and Improves Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction

Epigenetics in Heart Failure

Transcription Factors in Cardiac Remodeling: Latest Advances

Abstract P2091: Histone Deacetylase 6 (HDAC6) Inhibitor Improves Stress-Induced Cardiomyocyte Restructuring in Heart Failure with Preserved Ejection Fraction (HFpEF) in a Multimodal Manner Based on Single Nucleus RNA-seq (snRNA-seq) Analyses

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction

Targeting histone deacetylases for heart diseases

Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.